Clinical Trial Update: Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of durvalumab and SNDX-6532 after chemotherapy or radioembolization in patients with unresectable intrahepatic cholangi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• SNDX-6532

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Unresectable Intrahepatic Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-03-31